Apellis Present Pivotal VALIANT Results at Kidney Week Highlighting Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
October 30, 2024
WALTHAM, Mass. October 26, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that positive results from the Phase 3 VALIANT